Cassava Sciences Inc vs Omnicom Group Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Omnicom Group Inc. trades at $85.82 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 493.8× Cassava Sciences Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | OMC | |
|---|---|---|
Market Cap | $47.75M | $23.58B |
Sector | Health | Media |
52-Week High | $4.64 | $86.22 |
52-Week Low | $0.87 | $67.27 |
Enterprise Value | -$34.93M | $31.66B |
Dividend Yield | — | 3.72% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →